ClinicalTrials.gg
Active, not recruitingNCT06741397Updated Oct 5, 2026

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Phase 2 interventional study of CAB LA and New formulation of CAB LA in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 27 sites in 2 countries. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Other

Updated Oct 5, 2026Study completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
17th of 36
229 · median 200
Started
2024
with 2 others
Phase 2
8 of 36
none open now
Primary completion
2026-09
later than 8 of 12 live
Registered
32nd of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 17th largest by enrollment, is one of 3 that started in 2024, is one of 8 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 32nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir (CAB)
  • New formulation of CAB LA
  • CAB LA
  • HIV
  • 4-month dosing interval (Q4M)
  • Safety
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of obtaining , adolescent and adult participants weighing at least 35 kg.
  2. Participants must have a nonreactive test at Screening (rapid test, nonrapid HIV immunoassay, and HIV RNA) and enrollment (a rapid test, nonrapid HIV immunoassay, and HIV RNA).
  3. Participants who are at risk of acquiring HIV, defined as having had anal or vaginal sex in the past 6 months.
  4. Participants who are overtly healthy as determined by medical evaluation by a responsible and experienced physician, including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening.
  5. No alcohol or substance use that, in the opinion of the study investigator and medical monitor, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records).
  6. Participants who have received oral PrEP are eligible, but they must discontinue oral PrEP within 10 days of Day 1 visit.
  7. Male or female at birth, (transgender individuals are not excluded). use should align with local regulations. Participants assigned female at birth must not be pregnant or breastfeeding and must either not be of (POCBP) or use highly effective contraception. A POCBP must have a negative pregnancy test within 30 days before dosing.
  8. Participants must be >=16 years old, of legal age to consent to sexual intercourse, and capable of giving written informed consent. Adolescents must provide written informed assent/consent and/or obtain parental/guardian consent if not of legal age, as per site SOPs and IRB/EC policies.

Exclusion criteria

Exclusion Criteria:

  1. One or more reactive or positive test results at Screening or Enrollment, even if HIV infection was not confirmed.
  2. Participants who are breastfeeding or plan to become pregnant or breastfeed during the study.
  3. (ALT) >=3 times the (ULN).
  4. Evidence of active virus (HBV) infection.

    • Participants positive for HBsAg or HBV DNA are excluded.
    • Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.
  5. Unstable liver disease, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  6. History of hepatitis within last 6 months.
  7. Known history of liver cirrhosis with or without viral hepatitis co-infection.
  8. Participants with virus (HCV) co-infection will be allowed entry into this study if:

    • Liver enzymes meet entry criteria.
    • HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the primary endpoint (e.g., Month 13).
    • In the event that recent or imaging data is not available or inconclusive, the Fibrosis 4 (Fib-4) score will be used to verify eligibility:

      i. Fib-4 score greater than (>) 3.25 is exclusionary. ii. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 score Formula: (Age x AST) / ( x (sqr [ ALT]) It is approved by the Medical Monitor.

  9. Estimated of \<30 mL/min/1.73 m\^2 via CKD-EPIcr_R (2021) method.
  10. Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an compound.
  11. Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 [triglycerides or lipid abnormalities].
  12. Participants determined by the Investigator to have a high risk of seizures, A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
  13. Participant is currently participating in or has participated in a study with a compound or device that is not commercially available within 30 days of signing , unless permission from the Medical Monitor is granted.
  14. Presence of any history of allergy/sensitivity to any of the study drug.
  15. Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the investigator.
  16. Participant has an implant/enhancement (including fillers) at the area of proposed injection (e.g., gluteus medius); or tattoo or other dermatological condition overlying the area for IM (e.g., gluteus medius) or any other area which may significantly interfere with interpretation of injection site reactions.
  17. Current or anticipated need for chronic anti-coagulants or active coagulopathy (primary or iatrogenic) which would contraindicate IM injection.
  18. Ongoing or clinically relevant pancreatitis.
  19. Clinically significant cardiovascular disease or history of clinically significant cardiovascular disease.
  20. All participants will be screened for STIs (e.g., chlamydia, gonorrhea, trichomoniasis, syphilis). Participants with untreated infections are excluded. Participants may be rescreened at least 24 hours after completion of STI treatment.
  21. History or presence of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  22. Ongoing uncontrolled is excluded, whereas participants who have controlled localized malignancies may be included on agreement between the investigator and the Medical Monitor.
  23. Participants who in the investigator's judgment, poses a significant suicidality risk.
  24. Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  25. Any condition which, in the opinion of the Investigator or the medical monitor, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive IM medication.
  26. Co-enrollment in any other interventional research study or other concurrent studies which may have interfered with this study (as provided by self-report or other available documentation). Exceptions for non-interventional studies may be made if appropriate after consultation with the Medical Monitor.
  27. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
  28. Use of antiretroviral therapy (ART) for Postexposure Prophylaxis within the 90 days prior to Day 1.
  29. Use of CAB LA for PrEP at any time prior to Screening.
  30. Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
  31. Anticipated need for HCV therapy with interferon or any drugs that have potential for adverse drug:drug interactions with study treatment throughout the entire study period.
  32. Treatment with an HIV-1 preventive vaccine within 90 days of Screening.
  33. Participant is unlikely to adhere to the study procedures, keep appointments, is planning to relocate during the study, or remain on study through to its conclusion.
  34. Participants who are considered high-risk, meeting at least one of the following criteria:

    • Participant who has exchanged condomless sex for goods or money within the past 12 months prior to Screening.
    • Participant who has used recreational intravenous drugs within the past 12 months prior to Screening.
    • Participant who has participated in Chemsex practice (such as the use of cocaine, crack cocaine, methamphetamine, ketamine, 3,4-methlenedioxy-methamphetamine, GHB, mephedrone or prescription drugs apart from those prescribed by a licensed provider) within the past 6 months prior to Screening.
    • Participant with any STI in the last 6 months also reporting any partners for condomless sex.
    • Participant who has condomless sex with a serodiscordant partner who has a detectable viral load or is not on ART.
    • Participant with any other behavior assessed by the investigator as high-risk sexual behavior.
  35. Participant has in the last 14 days prior to Screening presented with signs and symptoms, which, in the opinion of the investigator, are suggestive of acute HIV infection. Participants may only be enrolled if clinical suspicion of HIV is ruled out with non-reactive results.
  36. Participant becomes a ward of state (e.g., child in care).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    CAB Group

    Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB LA at Month 3, Month 5 and every 4 months thereafter to Month 29.

    Drug: CAB LA · Drug: New formulation of CAB LA

Interventions

  • DrugCAB LA

    Injections administered IM gluteal.

  • DrugNew formulation of CAB LA

    Injections administered IM gluteal.

06

What researchers measure

Primary outcomes

  1. CAB trough concentrations for target of 1.05 microgram per milliliter (μg/mL) for men and 1.39 μg/mL for women

    CAB trough concentrations are evaluated at or above the target of 1.05 μg/mL for men and 1.39 μg/mL for women, once steady state has been achieved, but no earlier than Month 13 of the study.

    Time frame: From Month 13 to Month 25

Secondary outcomes

  1. CAB trough concentrations for target of 0.672 μg/mL for men and 0.683 μg/mL for women

    CAB trough concentrations are evaluated at or above the target of 0.672 μg/mL for men and 0.683 μg/mL for women.

    Time frame: At Month 1

  2. CAB trough concentrations for target of 1.05 μg/mL for men and 1.39 μg/mL for women following loading dose

    CAB trough concentrations are evaluated at or above the target of 1.05 μg/mL for men and 1.39 μg/mL for women.

    Time frame: From Month 3 to Month 33

  3. CAB plasma concentrations

    Blood samples are collected by visit.

    Time frame: At Day 1, Day 1+1Week (W), Month (M) 1, M1+1W, M2, M3, M3+1W, M4, M5, M5+1W, M6, M7, M8, M9, M9+1W, M10, M11, M13, M13+1W, M17, M17+1W, M21, M25, M29, and M33

  4. CAB trough concentrations for target of 4x PA-IC90

    CAB trough concentrations are evaluated at or above the target of 4 times (4x) PA-IC90. PA-IC90 is defined as protein-adjusted concentration at which 90% inhibition of viral replication is achieved.

    Time frame: At Months 1, 3, 5, 9, 13, 17, 21, 25, 29, and 33

  5. Percentage of participants with confirmed incident HIV infections

    Time frame: Up to Month 33

  6. Percentage of participants with Study Medication Satisfaction Questionnaire Status version (SMSQs) results

    SMSQs is a self-completion measure which is evaluating 11-items (i.e., satisfaction, side effects, demands, convenience, flexibility, understanding, lifestyle, recommend, continue, easy or difficult, discomfort or pain). SMSQs is self-administered at each planned study visit and prior to the study drug administration.

    Time frame: From Month 1 up to Month 33

  7. Percentage of participants with Adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: Up to Month 33

  8. Percentage of participants with AEs by severity

    Severity is graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening.

    Time frame: Up to Month 33

  9. Percentage of participants with laboratory abnormalities

    Time frame: Up to Month 33

  10. Percentage of participants with laboratory abnormalities by severity

    Severity is graded according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening.

    Time frame: Up to Month 33

  11. Percentage of participants with changes in laboratory parameters

    Time frame: Up to Month 33

07

Study locations

27 sites
  • GSK Investigational Site
    Birmingham, Alabama 35222, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90035, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    Doral, Florida 33172-2513, United States
  • GSK Investigational Site
    Ft. Pierce, Florida 34982-7148, United States
  • GSK Investigational Site
    Orlando, Florida 32803-1851, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Chicago, Illinois 60612-7230, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Berkley, Michigan 48072, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Hawthorne, New York 10532-2140, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401-1209, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • GSK Investigational Site
    Dallas, Texas 75246-2004, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    San Juan, 00909, Puerto Rico
  • GSK Investigational Site
    San Juan, 909, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Sep 2026, 20 months.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 20 months is close to that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Aug 2029, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 19, 2024
StartActual
Dec 20, 2024
Primary completionActual
Sep 9, 2026
CompletionEst.
Aug 30, 2029was Jan 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • GSK Investigational Site · Hawthorne, United States
Show 1 removed
  • GSK Investigational Site · Valhalla, United States
Oct 5, 2026
Study completion
Jan 10, 2029→Aug 30, 2029
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · Hawthorne, United States
    Show 1 removed
    • GSK Investigational Site · Valhalla, United States
    Study completion Jan 10, 2029→Aug 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06741397
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 20, 2024
Primary completion
Sep 9, 2026
Completion
Aug 30, 2029 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion